tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AMLX Stock Latest News

Amylyx price target raised to $25 from $17 at Guggenheim
The FlyAmylyx price target raised to $25 from $17 at Guggenheim
14d ago
AMLX
Amylyx Pharmaceuticals Announces $164 Million Stock Offering
PremiumCompany Announcements
Amylyx Pharmaceuticals Announces $164 Million Stock Offering
18d ago
8K
AMLX
Amylyx 17.5M share Spot Secondary priced at $10.00
PremiumThe Fly
Amylyx 17.5M share Spot Secondary priced at $10.00
19d ago
AMLX
Amylyx announces common stock offering, no amount given
PremiumThe Fly
Amylyx announces common stock offering, no amount given
19d ago
AMLX
Amylyx price target raised to $14 from $10 at BofA
PremiumThe Fly
Amylyx price target raised to $14 from $10 at BofA
1M ago
AMLX
Amylyx Pharmaceuticals Halts ORION Program for AMX0035
PremiumCompany AnnouncementsAmylyx Pharmaceuticals Halts ORION Program for AMX0035
1M ago
8K
AMLX
Amylyx to discontinue ORION program of AMX0035
Premium
The Fly
Amylyx to discontinue ORION program of AMX0035
1M ago
AMLX
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
Premium
Company Announcements
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
1M ago
AMLX
Amylyx Pharmaceuticals’ Promising Earnings Call Highlights
PremiumCompany Announcements
Amylyx Pharmaceuticals’ Promising Earnings Call Highlights
2M ago
AMLX
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements
PremiumRatings
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements
2M ago
AMLX
Amylyx Pharmaceuticals: Progress in Trials and Financials
PremiumCompany Announcements
Amylyx Pharmaceuticals: Progress in Trials and Financials
2M ago
AMLX
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial
PremiumCompany Announcements
Amylyx Pharmaceuticals Advances ALS Treatment with AMX0114 Clinical Trial
2M ago
AMLX
Amylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia
PremiumCompany AnnouncementsAmylyx Pharmaceuticals’ Phase 3 Study on Avexitide: A Potential Game-Changer for Post-Bariatric Hypoglycemia
2M ago
AMLX
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential
Premium
Ratings
Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential
2M ago
AMLX
Amylyx reports Q2 EPS (46c), consensus (45c)
Premium
The Fly
Amylyx reports Q2 EPS (46c), consensus (45c)
2M ago
AMLX
Amylyx Pharmaceuticals Advances Avexitide Study for Post-Bariatric Hypoglycemia
PremiumCompany Announcements
Amylyx Pharmaceuticals Advances Avexitide Study for Post-Bariatric Hypoglycemia
2M ago
AMLX
Amylyx Pharmaceuticals’ ALS Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Amylyx Pharmaceuticals’ ALS Study: A Potential Game-Changer for Investors
2M ago
AMLX
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating
PremiumRatings
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating
2M ago
AMLX
Amylyx presents new analyses from Phase 2, Phase 2b trials of avexitide
PremiumThe Fly
Amylyx presents new analyses from Phase 2, Phase 2b trials of avexitide
3M ago
AMLX
Amylyx resumed with a Buy at Goldman Sachs
PremiumThe FlyAmylyx resumed with a Buy at Goldman Sachs
3M ago
AMLX
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects
Premium
Ratings
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects
3M ago
AMLX
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
Premium
Company Announcements
Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
3M ago
AMLX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >